Reducing antidepressants’ side effects
Medicines used to treat depression, called selective serotonin reuptake inhibitors (SSRIs), can increase bleeding risk and bleeding time and disrupt platelet aggregation in the gastrointestinal tract. SSRIs prevent cells from taking up the neurotransmitter serotonin that has been released from cells by blocking the serotonin transporter (SERT). It is unclear how blocking SERT disrupts platelet aggregation.
Heidi Hamm , Ph.D., Ana Carneiro, Ph.D., and colleagues used pharmacological and genetic models to show that chronic SSRI treatment causes decreased levels of a serotonin receptor (5-HT2AR) on platelets. They showed that inhibiting SERT increases extracellular serotonin, which desensitizes the 5-HT2AR and reduces platelet activation.
These findings suggest a novel mechanism where prolonged use of SSRI medications results in reduced platelet aggregation. This provides useful insight into the effects of SSRIs and supports findings that drugs targeting the serotonin receptor may be used to reduce recurrent thrombosis by blocking platelet activation.
Original publication
Other news from the department science
![[Fe]-hydrogenase catalysis visualized using para-hydrogen-enhanced nuclear magnetic resonance spectroscopy](https://img.chemie.de/Portal/News/675fd46b9b54f_sBuG8s4sS.png?tr=w-712,h-534,cm-extract,x-0,y-16:n-xl)
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
